Q1 EPS Forecast for Agios Pharmaceuticals Lowered by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at Zacks Research cut their Q1 2025 earnings per share estimates for shares of Agios Pharmaceuticals in a report issued on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of ($1.64) per share for the quarter, down from their prior estimate of ($1.63). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.72) EPS, FY2025 earnings at ($6.77) EPS, Q1 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.41) EPS and FY2026 earnings at ($5.70) EPS.

Several other equities analysts also recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Up 9.6 %

Shares of AGIO opened at $42.69 on Monday. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58. The firm has a market capitalization of $2.43 billion, a P/E ratio of 3.76 and a beta of 0.80. The firm’s 50-day moving average is $50.06 and its two-hundred day moving average is $46.80.

Insider Buying and Selling

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. raised its position in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC lifted its holdings in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.